Lingyi Bio Wins '2024 China Biopharma Industry Chain Innovation Storm List' Annual Industry Attention Award for Rare Disease Drugs

On December 17, 2024, the "2024 (5th) China Biopharma Industry Chain Innovation Storm List" was released with significant impact, and Lingyi (Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as "Lingyi Biotech" or "the Company")'s LY-M001 injection was honored with the "Annual Industry Attention Rare Disease Drug" award. This accolade is not only an affirmation of Lingyi Biotech's work in the field of rare disease treatment but also a recognition of the team's relentless efforts and spirit of innovation.

The "China Biopharma Industry Chain Innovation Storm List" is initiated by the China Biopharma Industry Innovation and Translation Alliance (CBIITA Alliance), and since its launch in 2020, it has become one of the most authoritative and influential selection activities in the industry. The list gathers objective data and expert wisdom through multi-dimensional authoritative data analysis and expert perspective verification, aiming to establish industry benchmarks, stimulate innovative potential, and enrich the soil for innovation.

LY-M001 injection is a significant research achievement of Lingyi Biotech in the field of rare diseases, marking a major breakthrough for the company in the treatment of rare diseases. Lingyi Biotech will continue to adhere to the "patient-centered" philosophy, increase R&D investment, promote the development and marketing of more innovative drugs, and meet the unmet medical needs of patients with rare diseases.